Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.

